

Cambridge University Press

978-1-107-01320-9 - Cognitive Impairment in Schizophrenia: Characteristics, Assessment, and Treatment

Edited by Philip D. Harvey

Index

[More information](#)

Index

-
- ability
 - dysfunctional beliefs
 - affecting 91–92
 - motivation and negative symptoms 90–91
 - acetylcholine 269–270
 - acetylcholinesterase inhibitors 272
 - adolescents, relevance of
 - performance-based measures 262
 - affect recognition, studies of 131–132
 - affect recognition training 300
 - neural mechanisms of 307–308
 - affective saliency of stimuli, assessment issue 61
 - aging 110–111
 - cognitive processing, changes in 112–113
 - and dementia 113–114
 - sensory functioning, changes in 112
 - see also* older patients
 - alertness-promoting agent, modafinil 275
 - Alzheimer's disease (AD) 117
 - amphetamine treatment 275
 - anhedonia 100
 - anterior cingulate cortex (ACC), error/conflict detection 211–212
 - anticholinergic medication, negative effects on cognition 10, 309
 - antipsychotic medications
 - dopamine D2 receptor blockade 267
 - dosing effects of add-on compounds 278–279
 - effect on cognition 9–10
 - and emotion recognition 133–134
 - interference with effects of cognitive enhancers 278
 - apathy 100
 - assessment
 - affective saliency of tasks 61
 - of cognitive and functional skills 118–119
 - cognitive neuroscience approach 25–26
 - consensus batteries 61–62
 - experiential negative symptoms 93
 - informant-based reports of functional performance 119
 - issues requiring further study 121
 - repeated testing, bipolar disorders 62
 - standard cognitive measures, criticism of 11–12
 - see also* performance-based measures of functioning
 - assessment of cognition in schizophrenia
 - treatment studies 231
 - cognitive outcome measures 240
 - computerized tests 241–243
 - paper pencil batteries 240–241
 - current status of clinical trials 231–234
 - outcome measures and study designs 239
 - associative memory 208
 - attention 163–164
 - attitudes, dysfunctional 91–92
 - attributional style 86, 129–130
 - bipolar disorder 56
 - training programs targeting 300
 - auditory (dys)function 180
 - behavioral studies 180–181
 - neuropsychological approaches 181–182
 - normative age-related changes 111–112
 - predicting social cognition and outcome 88
 - auditory emotion recognition 181
 - auditory steady-state response (ASSR) 182
 - auditory training, Brain Fitness Program 296–297
 - awareness of illness 142–144
 - measurement of insight 150
 - measurement of neurocognition 150–152
 - meta-analysis
 - data analysis 145
 - discussion 149–150
 - limitations of studies included in 150
 - methods used 144–145
 - results 146–149
 - studies included in 152–156
 - AX-CPT task, executive processing/working memory 185
 - B-CATS (Brief Cognitive Assessment Tool for Schizophrenia) 241
 - BACS (Brief Assessment of Cognition in Schizophrenia) 240–241
 - BCA (Brief Cognitive Assessment) 241
 - beliefs, dysfunctional 91–92
 - BFP *see* Brain Fitness Program
 - bipolar disorder
 - functional impairment 262–263
 - genetics 167
 - neuropsychological impairments 70
 - social cognition 54–56

Cambridge University Press

978-1-107-01320-9 - Cognitive Impairment in Schizophrenia: Characteristics, Assessment, and Treatment

Edited by Philip D. Harvey

Index

[More information](#)

- bipolar disorder/schizophrenia
 - comparison
 - assessment issues 61–62
 - clinical remission 58–59
 - diagnostic criteria 50–51
 - functional outcomes,
 - predictors of 59–61
 - and history of psychosis 59
 - negative symptoms 58
 - neurophysiological findings
 - 56–57
 - profile and course of
 - cognitive deficit 51–54
 - sex differences 57–58
 - trans-disorder effects 167
- blunted affect 100
- brain-derived neurotrophic
 - factor (BDNF), effect of
 - training on levels 309
- Brain Fitness Program (BFP)
 - 296–297
 - and improvements in neural
 - operations during early
 - auditory processes
 - 304–305
 - and increase in serum BDNF
 - and D-serine levels 309
- “brain reserve capacity” theory
 - 72
- brain volume loss, in persistent
 - psychosis 118
- Brief Assessment of Cognition
 - in Schizophrenia
 - (BACS) 240–241
- Brief Cognitive Assessment
 - (BCA) 241
- Brief Cognitive Assessment
 - Tool for Schizophrenia
 - (B-CATS) 241
- brief version of UPSA 121, 257,
 - 261–262
- CACNA1C gene 168
- Cambridge Neuropsychological
 - Test Automated Battery
 - (CANTAB) 242
- cannabinoid receptor agents
 - 277
- chronicity of illness, impact on
 - cognition 10
- clinical remission 58–59
- clinical trials on cognition
 - 231–234
- co-primary measures of
 - functional capacity
 - 238–239
- design of 234–236
- early phase trials
 - 236–237
- further cognitive outcome
 - measures 240–241
- implementation issues 235
 - trials using cognitive
 - neuroscience tests 238
- interview-based measures
 - 239
- Cognitive Assessment
 - Interview (CAI) 239
- cognitive deficits/impairments
 - course of 52–54
 - effect sizes 4–5
 - heritability of 163
 - included as a dimension of
 - psychosis 80
 - independence from
 - psychosis 10–13
 - profile of 51–52
 - as stable traits in
 - schizophrenia 163
 - see also* generalized cognitive
 - deficits
- cognitive domains, similarities
 - and differences between
 - schizophrenia and
 - comparison groups
 - 38–41
- Cognitive Drug Research
 - (CDR) battery
 - 242–243
- cognitive enhancement,
 - pharmacological
 - approaches 266–267
 - compounds used in previous
 - studies 272–277
 - methodology 270–271
 - negative results, reasons for
 - 277–279
 - neurotransmitter
 - interventions 267–270
- Cognitive Enhancement
 - Therapy (CET) 289
- cognitive neuropsychiatry
 - 12–13
- cognitive neuroscience 25–26,
 - 194
- models of episodic memory
 - 206–207
- models of working memory
 - 195
- cognitive processing, normative
 - age-related changes
 - 112–113
- cognitive remediation and
 - vocational
 - rehabilitation 102–103
- cognitive training
 - see* computerized
 - cognitive training
- cognitively intact schizophrenia
 - 16–17
 - explanations for 72
 - and symptom severity 11
- CogPack, computerized
 - training 290–295
- CogRehab software,
 - computerized training
 - 288
- CogState schizophrenia battery
 - 242
- community functioning 87,
 - 92–93
- contribution of social
 - cognition 132–133
- performance-based
 - assessment 255–257
- competence *see* functional
 - capacity; social
 - competence
- computational modeling and
 - ph-fMRI 215–218
- computerized cognitive
 - training 284
 - important future directions
 - 310–311
 - neurobiological effects of 304
 - prior meta-analytic work
 - 284–286
- programs 287
 - BPF (Brain Fitness
 - Program) 296–297
 - CogPack exercises, studies
 - using 290–295
 - CogRehab exercises,
 - studies using 288–290
 - comparative effects of
 - 297–298
- NEAR
 - (Neuropsychological &
 - Educational Approach
 - to Remediation)
 - 295–296
 - psychophysical findings 308
 - serum biomarker and genetic
 - findings 309–310
- computerized social cognitive
 - training 298–300
 - neurobiological effects of
 - 307–308

318	Index	
computerized social cognitive training (cont.)	<i>see also</i> persecutory delusions	dual process vs. “standard” model of schizophrenia 6
with social cognitive group treatment 300	dementia 113–115, 266–267	dysfunctional beliefs and negative symptoms 91–92
summary of 300–304	dementia praecox, symptoms 2	
computerized testing 241–243	demographic issues	
COMT polymorphisms	age of clinical trial samples 232–233	educational attainment and work functioning 99
and cognitive improvement after training 309–310	sex differences, comparison studies 57–58	EFB (Everyday Functioning Battery) 259
and pharmacological issues 279	depressive symptoms 75–79	effect size, funnel plot 147–149
conflict detection, executive control 211–212	diagnostic criteria 50–51	Emotion Trainer, computerized program 299–300
context processing 209–210	Direct Assessment of Functional Status scale (DAFS) 253–254	emotional processing/ emotional intelligence 86, 128–129
Continuous Performance Tasks (CPT), inheritance of attentional deficits 163–164	direct observation of functional tasks, problems with 251	bipolar disorder 54–55
control, proactive and reactive 210–211	disorganization/disorganized symptoms	computerized training in 298–301
control task issues in experimental designs 131–132	links to cognitive domains 75–80	face processing tasks, methodological issues 131–132
copy number variants (CNVs), rare variation 161, 168–169	relationship to executive functions 74–75	link to community functioning 132
cortical disinhibition, ketamine effects 214–215	relationship to ToM abilities 128	oxytocin improving 134
cross-cultural relevance of performance-based measures 262	distraction, suppression of, WM tasks 199–200, 204–205	prosodic-level impairments 180–181
CTNTRICS (Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia) 236–237	dopamine 267–268	visual deficits, contribution of 185
cultural differences	D1 agonists, administration problems 279	empathy, bipolar disorder 56
in generalized cognitive deficits 35	disruption by glutamatergic dysregulation 269	employment <i>see</i> work functioning
performance-based measures 262	dorsolateral prefrontal cortex (DLPFC)	encoding in episodic memory, neural correlates 206–208
D-serine, training increasing levels of 309	and ACC activity, executive control deficits 212	encoding deficits, working memory 196–199
davunetide, neurogenesis promoting 277	inverted-U hypothesis, working memory 200–202	and interference control deficits 199
declarative memory, ketamine effects 178	post-mortem studies 214–215	neural evidence for 202–203
default mode network (DMN) 204	and proactive control 211	role of default mode network (DMN) 204
defeatist beliefs 92	reduced activation during WM tasks 200	endophenotype approach, genetics research 162
delusions	role in distraction suppression, WM tasks 204	Enriched Supportive Therapy (EST) 289
interference with work 99–100	role in episodic memory 208	episodic memory (EM)
	dose of medications 278–279	cognitive neuroscience models 206–207
	drugs <i>see</i> medication; pharmacological approaches to cognitive enhancement	genetic studies 165–166
	DTNBP1 gene studies 166–167	impairments and neural correlates 207–208
		error monitoring, executive control 211–212

- event-related potentials (ERP)
 - assessment of early auditory processing 89
 - bipolar disorder/
 - schizophrenia comparison 56–57
- Everyday Functioning Battery (EFB) 259
- exceptionality
 - and verbal superiority 8
 - versus normality 5–7
- executive control dysfunction
 - 209
 - conflict detection/error monitoring 211–212
 - context processing 209–210
 - proactive and reactive control 210–211
- experiential negative symptoms 93
- experimental designs, control
 - task issues 131–132
- externalizing attributional bias
 - 13, 129–130
- eye movement, deficits in
 - smooth pursuit 56–57
- face processing tasks,
 - methodological issues 131–132
- facial emotion recognition
 - computerized training in 298–300
 - early visual deficits impairing 185
- factor analyses
 - bipolar disorder and schizophrenia comparison 51–52
 - of cognitive domains 38–41
 - social cognition and neurocognition 87–88, 131
- false beliefs *see* delusions;
 - theory of mind (ToM)
- familial pattern of deficits
 - 35–37
- filtering deficits, working
 - memory 199, 204–205
- first episode psychosis (FEP)
 - attrition rates in
 - computerized tests 241–242
 - cognitive deficits in 10
 - psychosis studies 70
- symptom dimensions and
 - cognitive functioning 76–78
- fMRI (functional magnetic resonance imaging)
 - computerized cognitive training, improved activation following 305–307
 - computerized social cognition training 307–308
 - pharmacological fMRI (ph-fMRI) 215–218
 - working memory (WM) 200–206
- Food and Drug Administration (FDA), approval criteria
 - for cognitive enhancing drugs 270–271
- functional capacity 90–91
 - co-primary measures 238–239
 - informant-based reports 119
 - interview-based measures 239
 - link to defeatist beliefs 92
 - performance-based measures 119–121
 - role in identifying determinants of disability 248–249
 - self-report measures, biases in 249–250
- functional milestones, limited
 - responsiveness of 250–251
- functional outcome and
 - neurocognition 85–86
 - bipolar disorder–schizophrenia comparison 59–61
- cognitive ability as key
 - predictor of 4, 14–15
- contribution of social
 - cognition to 132–133
- integrating perception,
 - ability and motivation 92–93
- perceptual processes
 - predicting 88
- role of negative symptoms
 - 90–92
- social cognition as mediator
 - between 86–88
- funnel plot, publication bias 147–149
- GABA (gamma-aminobutyric acid)
 - and cortical disinhibition 214–215
 - interventions 277
 - reduced signaling levels 269
- general intelligence, heritability
 - of 166
- generalized cognitive deficits
 - 24–27, 32, 194
 - around the globe 35
 - factor analyses of cognitive domains 38–41
 - general discussion and conclusion 41–43
 - meta-analysis findings 27–32
 - over past three decades 32–34
 - pattern within families 35–37
 - treatment issues 42–43
 - vs. specific impairments 131–132
- genetic association studies
 - 166–169
 - COMT polymorphism and cognitive improvement after training 309–310
- genetic factors
 - attention 163–164
 - cognitive deficits
 - as candidate endophenotype 162–163
 - heritability of 42, 163
 - as stable traits 163
 - episodic memory 165–166
 - general intelligence 166
 - working memory 164–165
- global cognitive impairment
 - see* generalized cognitive deficits
- glutamatergic interventions
 - 273–274
- glutamatergic
 - neurotransmission, disturbance of 176–177
 - and higher cognitive dysfunction 177–178
 - and impaired sensory processing 178–186
- group treatment, social
 - cognitive skills training 300

320	Index
hallucinations, effect on work functioning 99	Kraepelin, E., dementia praecox, symptoms 2
heritability - of cognitive deficits 163 - of schizophrenia 161–162 <i>see also</i> genetic factors	lamotrigine treatment 274
hierarchical model of cognitive domain structure 38–41	learning and declarative memory, ketamine response 178
hippocampus - learning and declarative memory 178 - preservation of gray matter following CET 307 - role in episodic memory 206–207 - and visual dysfunction 184–185 - and ZNF804A risk variant 167–168	long-term memory 112–113
hospitalization, impact on functional outcome 118	magnetoencephalography (MEG) studies 304–305
illness awareness <i>see</i> awareness of illness	magnitude/severity of impairment 52–53
Independent Living Scales (ILS) 260–261	magnocellular pathway, visual dysfunction 182–184
informant-based reports of functional performance 119 variation in informant validity 250	maintenance deficits, working memory 196–199
in-person observation of functional activity, problems with 251	mechanisms contributing to 199–200
<i>see also</i> awareness of illness	neuroimaging evidence 202–205
intelligence, heritability of 166	Maryland Assessment of Social Competence (MASC) 254
interference control deficits, WM 199–200	MATRICES Consensus Cognitive Battery (MCCB) 234–236
interview-based measures 239, 261	MATRICES CT study 261
inverted U hypothesis, prefrontal recruitment in WM 200–202	MATRICES (Measurement and Treatment Research to Improve Cognition in Schizophrenia) project 61–62, 119, 231, 233, 271
JTC (jumping to conclusions) effect 12–13	medial prefrontal cortex, activation during reality-monitoring training 307
ketamine 213–214 - behavioral effects 214 - neurobiological effects 214–215 - specificity of response 178 - task-switching performance in monkeys 178–179	medication 42–43 - administration problems 279 - doses, effect on efficacy 278–279 - effect on cognition 9–10, 309 - and emotion recognition 133–134 - interference with cognitive enhancers 278
	Medication Management Ability Assessment (MMAA) 258
	memory - Bleuler’s work 1–2 - effect of medication on 10 - normative age-related changes 112–113 <i>see also</i> episodic memory (EM); working memory (WM)
	mental state attribution 87 <i>see also</i> theory of mind (ToM)
	meta-analyses, cognitive deficit findings - comparative findings 4–5 - global cognition 27–32
	meta-analysis, insight–cognition link 143–150 studies included in analysis 152–156
	meta-analytic studies of cognitive training 284–286
	Micro-Expressions Training Tool (METT) 298–299
	Micro-Module Learning Test (MMLT) 254–255
	mild cognitive impairment (MCI) 114
	mismatch negativity (MMN) 89, 182
	missing data, computerized tests 241–242
	MK-0777 treatment 277
	modafinil treatment 275
	motion detection deficits 183
	motivation, ability and negative symptoms 90–91
	muscarinic receptor systems 269–270
	N-methyl-D-aspartate (NMDA) <i>see</i> NMDA receptor dysfunction
	NEAR (Neuropsychological and Educational Approach to Remediation) 295–296
	negative symptoms 58 - ability and motivation 90–91 - correlation with cognitive domains 74–76 - and dysfunctional beliefs 91–92 - experiential, reduced motivation 93 - interference with work 99–100
	neurobiological determinants of cognition 176 glutamatergic contributions to impaired sensory processing 178

	Index	321
auditory function 180–182	and cognitive deficits 177–178	Direct Assessment of Functional Status scale (DAFS) 253–254
visual dysfunction 182–186	hypo-function hypothesis, ketamine effects 214–215	Everyday Functioning Battery (EFB) 259
glutamatergic determinants of higher cognitive dysfunction 177–178	and visual deficits 182–186	Independent Living Scales (ILS) 260–261
PCP/NMDA model of schizophrenia 176	non-transmitter interventions 277	Maryland Assessment of Social Competence (MASC) 254
summary 186	noradrenergic interventions 274–275	Medication Management Ability Assessment (MMAA) 258
Neurocognitive Enhancement Therapy (NET) 290	normality 6–8	Micro-Module Learning Test (MMLT) 254–255
neurocognitive measures 152–156	novel relational information, encoding and retrieval of, role of hippocampus 206–207	Social Skills Performance Assessment (SSPA) 257–258
neurodegenerative disorders 114, 117	older patients 110–111, 121	Test of Adaptive Behavior in Schizophrenia (TABs) 259–260
neurodevelopmental hypotheses	assessment of cognitive and functional skills 118–121	UCSD Performance-Based Skills Assessment (UPSA) 255
cognitive impairment 41	and dementia 114–115	UPSA-Brief 257
cognitively intact schizophrenia 72	functional performance 115–118	summary and conclusions 263
neurogenesis-promoting compounds 277	hospitalization 118	use of in treatment studies 261
neuroimaging	<i>see also</i> aging	performance normality, definition and prevalence of 6–8
magnetoencephalography (MEG) studies 304–305	oxytocin, improving emotion recognition 134	persecutory delusions and attributional style 56, 86, 129–130
voxel-based morphometry (VBM) 307	paper-pencil test batteries 240–241	JTC (jumping to conclusions) effect 12–13
<i>see also</i> fMRI (functional magnetic resonance imaging)	parvocellular pathway, visual dysfunction 182–183	personalizing attributional bias 56, 129–130
neurophysiological findings 56–57, 181–182	PCP (phencyclidine)/NMDA model of schizophrenia 176–177	pharmacokinetics 279
visual dysfunction 183	perception	pharmacological approaches to cognitive enhancement 266
working memory abnormalities 202–204	integrating with ability and motivation 92–93	cognitive enhancement methodology 270–271
neuroplasticity and decreased BDNF functioning 309	perceptual closure, visual function 184	mechanisms of action studied 272–273
Neuropsychological and Educational Approach to Remediation (NEAR) 295–296	as predictor of social cognition and outcome 88	acetylcholinesterase inhibitors 272
neurotransmitters 266–267	<i>see also</i> social perception	amphetamine 275
acetylcholine 269–270	performance-based measures of functioning 119–121, 248	cannabinoid receptor agents 277
dopamine 267–268	advantages of over other modalities 249–251	GABA-based interventions 277
GABA 269	future directions 261–263	
glutamate 268–269	limitations of 251	
non-viable as cognitive enhancers 279	role in identifying determinants of disability 248–249	
nicotinic agonists 272–273	selected measures 251–252	
nicotinic receptor density, alteration of 269		
NMDA receptor dysfunction 176–177		
and auditory deficits 180–182		

- www.cambridge.org

- domains of 127–130
- and functional outcome
 - 86–88
- future directions 133–135
- and neurocognition
 - 130–133
- perception as correlate and predictor of 88
- role of ZNF804A risk variant
 - 168
- and work problems 100
 - see also* computerized social cognitive training
- Social Cognitive Interaction Training (SCIT) 300
- Social Cognitive Skills Training (SCST) 300
- social competence
 - assessment of 254
 - deficits, and work problems 100
- social perception 86
 - bipolar disorder 55
 - computerized training 300–304
 - see also* social cognition
- Social Skills Performance Assessment (SSPA) 257–258
- specific/core cognitive deficits 194
- “standard” vs. dual process models 6
- Standards for Educational and Psychological Testing* (APA) 235
- standards for psychological testing 235
- stimulants and alertness agents 267
 - amphetamines 275
 - modafinil 275
 - nicotinic agonists 272–273
- Subtle Expressions Training Tool (SETT) 298–299
- symptom dimensions in
 - psychosis 69, 73–74
 - and neuropsychological functioning 69–73
 - psychotic disorders 76–79
 - schizophrenia studies 74–76
- summary and conclusion 79–80
- symptoms
 - interference with work 99–100
 - severity of, and cognition 11–12
 - see also* negative symptoms
- targeted pro-cognitive treatments 42–43
- task switching, neural
 - correlates of 177–179
- temporal differences in
 - generalized deficits 32–34
- Test of Adaptive Behavior in Schizophrenia (TABS) 259–260
- theory of mind (ToM) 128
 - bipolar disorder 55
 - cognitive basis of persecutory beliefs 13
 - link to insight 151–152
 - mental state attribution 87
- tone-of-voice, impaired
 - discrimination 180–181
- tone matching 180–181
- training *see* computerized cognitive training
- Training of Affect Recognition (TAR) 299
- translational cognitive neuroscience 193
 - neural correlates of cognitive dysfunction 193–194
 - episodic memory 206–208
 - executive control 209–212
 - working memory 195–206
- working memory example 212–213
 - computational modeling and ph-fMRI 215–218
 - pharmacological neuroimaging (ph-fMRI) 213–215
- treatment of cognitive deficits 62
- twin studies
 - cognitive deficits 42, 163
 - working memory 164–165
- two pathway model 90–91
- UCSD Performance-Based Skills Assessment (UPSA) 255
 - use in older patients 117, 119–120
- unaffected siblings, comparison of cognitive deficits 35–37
- UPSA-Brief (UPSA-B) 121, 257, 261–262
- Validation of Intermediate Measures (VIM) study 238–239
- validity
 - of cognitive measures as outcome predictors 14–15
 - of self-reports 250
 - of symptom dimensions 73–74
- verbal learning and memory, training program 296–297
- verbal memory processes
 - Brain Fitness Program improving 296–297
 - neural activation following computerized training 305–306
- verbal superiority study 8
- visual contour integration 89, 185
- visual (dys)function
 - 182–183
 - cognitive consequences of early 183–186
 - normative age-related changes 111–112
 - predicting social cognition and outcome 88
- visual training, improving visual memory 308
- vocational rehabilitation 101–103, 295, 297
- voxel-based morphometry (VBM) 307
- work functioning 98–99
 - cognitive remediation and vocational rehabilitation 102–103
 - effect of cognitive impairments 101
 - premorbid functioning and educational attainment 99
 - psychotic and negative symptoms 99–100
 - social competence problems 100

324	Index	
work functioning (cont.) summary and conclusions 103–105 supported employment 101–102	cognitive neuroscience models 195 computational modeling and ph-fMRI 215–218 context processing role 209–210 heritability of 164–165 neurocognitive enhancement therapy improving 289–290 neuroimaging findings 200 neural deficits across phases of WM 202–204	prefrontal recruitment 200–202 summaries 205–206, 218 younger people greater potential neuroplasticity 232 relevance of current test measures 262 ZNF (zinc finger protein) 804A gene 167–168